Several lines of evidence suggest the use of novel therapy, such as CAPTEM, PRRT, EVE, immunotherapy, EGFR inhibitors, CDK2 inhibitors, and RA, could be valuable strategies for long-term tumor control. This evidence concerns the gene CDK2 and neoplasm.